| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA740: Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer |
|
Medicine details |
|
| Medicine name | apalutamide (Erleada®) |
| Formulation | 60 mg tablet |
| Reference number | 3133 |
| Indication | Treatment of metastatic hormone-sensitive prostate cancer in combination with androgen deprivation therapy |
| Company | Janssen-Cilag ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 22/06/2020 |
| NICE guidance | |